Gut Reactions #9 – New treatment for active ulcerative colitis (UC)
Tofacitinib is a new JAK inhibitor taken by mouth 10mg twice daily. Recent trials (OCTAVE) have shown significant benefit in patients with moderately active UC. The patients had previous failure or intolerance to conventional treatments. Patients receiving tofacitinib were significantly more likely to have a clinical response, healing of the colon or achieve remission than those given placebo tablets at weeks 2, 4 and 8. While this drug has been around some time, this is the latest and largest trial that has produced promising results. It is hoped that it will be licensed and made available for appropriate or selected patients towards the end of 2017.